AU2004248192A1 - Novel modified corin molecules having substitute activation sequences and uses thereof - Google Patents

Novel modified corin molecules having substitute activation sequences and uses thereof Download PDF

Info

Publication number: AU2004248192A1
Authority: AU; Australia
Prior art keywords: molecule; corin; sequence; modified; molecules
Prior art date: 2003-06-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2004248192A

Other languages

English (en)

Inventor

Qingyu Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Schering AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-11

Filing date

2004-06-09

Publication date

2004-12-23

2004-06-09 Application filed by Schering AG filed Critical Schering AG

2004-12-23 Publication of AU2004248192A1 publication Critical patent/AU2004248192A1/en

2006-09-21 Assigned to SCHERING AKTIENGESELLSCHAFT reassignment SCHERING AKTIENGESELLSCHAFT Request for Assignment Assignors: SCHERING AKITENGESELLSCHAFT

Status Abandoned legal-status Critical Current

Links

102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 title claims description 416
101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 title claims description 416
230000004913 activation Effects 0.000 title claims description 121
210000004027 cell Anatomy 0.000 claims description 145
235000001014 amino acid Nutrition 0.000 claims description 133
150000001413 amino acids Chemical class 0.000 claims description 125
101000952934 Homo sapiens Atrial natriuretic peptide-converting enzyme Proteins 0.000 claims description 101
239000013598 vector Substances 0.000 claims description 80
150000007523 nucleic acids Chemical class 0.000 claims description 77
238000000034 method Methods 0.000 claims description 75
239000012634 fragment Substances 0.000 claims description 66
102000039446 nucleic acids Human genes 0.000 claims description 63
108020004707 nucleic acids Proteins 0.000 claims description 63
108010013369 Enteropeptidase Proteins 0.000 claims description 51
102100029727 Enteropeptidase Human genes 0.000 claims description 50
108020004414 DNA Proteins 0.000 claims description 44
108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
125000003729 nucleotide group Chemical group 0.000 claims description 40
239000002773 nucleotide Substances 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 36
102000035195 Peptidases Human genes 0.000 claims description 28
108091005804 Peptidases Proteins 0.000 claims description 28
239000013612 plasmid Substances 0.000 claims description 27
239000004365 Protease Substances 0.000 claims description 26
235000002639 sodium chloride Nutrition 0.000 claims description 24
206010019280 Heart failures Diseases 0.000 claims description 23
102000012479 Serine Proteases Human genes 0.000 claims description 23
108010022999 Serine Proteases Proteins 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 21
206010007559 Cardiac failure congestive Diseases 0.000 claims description 19
239000008194 pharmaceutical composition Substances 0.000 claims description 19
230000000295 complement effect Effects 0.000 claims description 18
102000004190 Enzymes Human genes 0.000 claims description 17
108090000790 Enzymes Proteins 0.000 claims description 17
229940088598 enzyme Drugs 0.000 claims description 17
230000003197 catalytic effect Effects 0.000 claims description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 15
241000238631 Hexapoda Species 0.000 claims description 13
238000001415 gene therapy Methods 0.000 claims description 13
241000196324 Embryophyta Species 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
241001529936 Murinae Species 0.000 claims description 11
108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
-1 aerosin Proteins 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
108090001101 Hepsin Proteins 0.000 claims description 10
102000004989 Hepsin Human genes 0.000 claims description 10
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
235000018417 cysteine Nutrition 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 8
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
235000019359 magnesium stearate Nutrition 0.000 claims description 8
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
230000001580 bacterial effect Effects 0.000 claims description 7
230000036772 blood pressure Effects 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 7
201000000464 cone-rod dystrophy 2 Diseases 0.000 claims description 7
210000004962 mammalian cell Anatomy 0.000 claims description 7
241000283690 Bos taurus Species 0.000 claims description 6
101000598058 Homo sapiens Transmembrane protease serine 11D Proteins 0.000 claims description 6
108090000190 Thrombin Proteins 0.000 claims description 6
210000003527 eukaryotic cell Anatomy 0.000 claims description 6
102000014108 human airway trypsin-like protease Human genes 0.000 claims description 6
108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 claims description 6
229960004072 thrombin Drugs 0.000 claims description 6
241000271566 Aves Species 0.000 claims description 5
241000282465 Canis Species 0.000 claims description 5
241000283073 Equus caballus Species 0.000 claims description 5
241000282324 Felis Species 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 5
108090000631 Trypsin Proteins 0.000 claims description 5
102000004142 Trypsin Human genes 0.000 claims description 5
239000002502 liposome Substances 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
239000012588 trypsin Substances 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
208000031229 Cardiomyopathies Diseases 0.000 claims description 4
241000206602 Eukaryota Species 0.000 claims description 4
108010010803 Gelatin Proteins 0.000 claims description 4
101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 claims description 4
102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 claims description 4
108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 4
239000000839 emulsion Substances 0.000 claims description 4
239000008273 gelatin Substances 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
235000011852 gelatine desserts Nutrition 0.000 claims description 4
239000003921 oil Substances 0.000 claims description 4
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
208000006029 Cardiomegaly Diseases 0.000 claims description 3
108090000317 Chymotrypsin Proteins 0.000 claims description 3
108010088842 Fibrinolysin Proteins 0.000 claims description 3
108090001126 Furin Proteins 0.000 claims description 3
102000004961 Furin Human genes 0.000 claims description 3
101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims description 3
102000001399 Kallikrein Human genes 0.000 claims description 3
108060005987 Kallikrein Proteins 0.000 claims description 3
102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims description 3
101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims description 3
208000009525 Myocarditis Diseases 0.000 claims description 3
108010067372 Pancreatic elastase Proteins 0.000 claims description 3
102000016387 Pancreatic elastase Human genes 0.000 claims description 3
235000021355 Stearic acid Nutrition 0.000 claims description 3
102100031989 Transmembrane protease serine 2 Human genes 0.000 claims description 3
108060005989 Tryptase Proteins 0.000 claims description 3
102000001400 Tryptase Human genes 0.000 claims description 3
230000009787 cardiac fibrosis Effects 0.000 claims description 3
229960002376 chymotrypsin Drugs 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
150000002334 glycols Chemical class 0.000 claims description 3
208000018578 heart valve disease Diseases 0.000 claims description 3
208000031225 myocardial ischemia Diseases 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
229940012957 plasmin Drugs 0.000 claims description 3
201000011461 pre-eclampsia Diseases 0.000 claims description 3
210000001236 prokaryotic cell Anatomy 0.000 claims description 3
239000008117 stearic acid Substances 0.000 claims description 3
239000000454 talc Chemical class 0.000 claims description 3
235000012222 talc Nutrition 0.000 claims description 3
229910052623 talc Inorganic materials 0.000 claims description 3
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 claims description 2
101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 claims description 2
102000000185 SRCR domains Human genes 0.000 claims description 2
108050008568 SRCR domains Proteins 0.000 claims description 2
239000003114 blood coagulation factor Substances 0.000 claims description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
239000008116 calcium stearate Chemical class 0.000 claims description 2
235000013539 calcium stearate Nutrition 0.000 claims description 2
239000004927 clay Substances 0.000 claims description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
239000004005 microsphere Substances 0.000 claims description 2
235000013336 milk Nutrition 0.000 claims description 2
239000008267 milk Substances 0.000 claims description 2
210000004080 milk Anatomy 0.000 claims description 2
235000019198 oils Nutrition 0.000 claims description 2
239000002953 phosphate buffered saline Substances 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
239000008174 sterile solution Substances 0.000 claims description 2
235000000346 sugar Nutrition 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
235000019871 vegetable fat Nutrition 0.000 claims description 2
239000000080 wetting agent Substances 0.000 claims description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
108020001778 catalytic domains Proteins 0.000 claims 1
230000002538 fungal effect Effects 0.000 claims 1
229940024606 amino acid Drugs 0.000 description 122
108090000623 proteins and genes Proteins 0.000 description 76
101800001288 Atrial natriuretic factor Proteins 0.000 description 63
101800001890 Atrial natriuretic peptide Proteins 0.000 description 63
102400001282 Atrial natriuretic peptide Human genes 0.000 description 63
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 63
239000013604 expression vector Substances 0.000 description 50
108090000765 processed proteins & peptides Proteins 0.000 description 46
238000012217 deletion Methods 0.000 description 42
230000037430 deletion Effects 0.000 description 42
102000004169 proteins and genes Human genes 0.000 description 42
238000003776 cleavage reaction Methods 0.000 description 39
235000018102 proteins Nutrition 0.000 description 39
230000007017 scission Effects 0.000 description 39
102000004196 processed proteins & peptides Human genes 0.000 description 34
125000003275 alpha amino acid group Chemical group 0.000 description 32
229920001184 polypeptide Polymers 0.000 description 28
239000003636 conditioned culture medium Substances 0.000 description 21
238000012545 processing Methods 0.000 description 20
125000000539 amino acid group Chemical group 0.000 description 19
230000004927 fusion Effects 0.000 description 19
241000699800 Cricetinae Species 0.000 description 18
230000000694 effects Effects 0.000 description 18
230000003612 virological effect Effects 0.000 description 18
210000004899 c-terminal region Anatomy 0.000 description 16
239000004615 ingredient Substances 0.000 description 16
108091033319 polynucleotide Proteins 0.000 description 16
102000040430 polynucleotide Human genes 0.000 description 16
239000002157 polynucleotide Substances 0.000 description 16
210000002700 urine Anatomy 0.000 description 16
241000700605 Viruses Species 0.000 description 15
230000001177 retroviral effect Effects 0.000 description 15
238000001262 western blot Methods 0.000 description 15
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
108010062466 Enzyme Precursors Proteins 0.000 description 14
102000010911 Enzyme Precursors Human genes 0.000 description 14
238000005516 engineering process Methods 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
238000000338 in vitro Methods 0.000 description 13
239000000758 substrate Substances 0.000 description 13
108020004705 Codon Proteins 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
230000001756 cardiomyopathic effect Effects 0.000 description 12
239000000047 product Substances 0.000 description 12
230000002441 reversible effect Effects 0.000 description 12
238000009396 hybridization Methods 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000003556 assay Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
230000005714 functional activity Effects 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
239000011734 sodium Substances 0.000 description 9
238000011282 treatment Methods 0.000 description 9
241000701161 unidentified adenovirus Species 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 8
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
238000010276 construction Methods 0.000 description 8
239000003446 ligand Substances 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
238000013519 translation Methods 0.000 description 8
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 7
241000701022 Cytomegalovirus Species 0.000 description 7
108010070675 Glutathione transferase Proteins 0.000 description 7
102000005720 Glutathione transferase Human genes 0.000 description 7
108010001336 Horseradish Peroxidase Proteins 0.000 description 7
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
108091081024 Start codon Proteins 0.000 description 7
108020005038 Terminator Codon Proteins 0.000 description 7
210000004413 cardiac myocyte Anatomy 0.000 description 7
239000000969 carrier Substances 0.000 description 7
239000003623 enhancer Substances 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000000523 sample Substances 0.000 description 7
230000028327 secretion Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
238000001890 transfection Methods 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
239000004475 Arginine Substances 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
102000006601 Thymidine Kinase Human genes 0.000 description 6
108020004440 Thymidine kinase Proteins 0.000 description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
235000003704 aspartic acid Nutrition 0.000 description 6
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
230000037396 body weight Effects 0.000 description 6
238000002659 cell therapy Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
238000001802 infusion Methods 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
239000003826 tablet Substances 0.000 description 6
108010060175 trypsinogen activation peptide Proteins 0.000 description 6
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
208000004880 Polyuria Diseases 0.000 description 5
241000714474 Rous sarcoma virus Species 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
241000700584 Simplexvirus Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
235000009582 asparagine Nutrition 0.000 description 5
229960001230 asparagine Drugs 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000001086 cytosolic effect Effects 0.000 description 5
230000035619 diuresis Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
239000008101 lactose Chemical class 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
239000003550 marker Substances 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
239000007758 minimum essential medium Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
108010036927 trypsin-like serine protease Proteins 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
230000004568 DNA-binding Effects 0.000 description 4
108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 4
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
108010001831 LDL receptors Proteins 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
239000005089 Luciferase Substances 0.000 description 4
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
108020001621 Natriuretic Peptide Proteins 0.000 description 4
102000004571 Natriuretic peptide Human genes 0.000 description 4
101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
101710176177 Protein A56 Proteins 0.000 description 4
102100036407 Thioredoxin Human genes 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
239000004473 Threonine Substances 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
108091005948 blue fluorescent proteins Proteins 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
230000029142 excretion Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
239000005090 green fluorescent protein Substances 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
239000000185 hemagglutinin Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000692 natriuretic peptide Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
229940068918 polyethylene glycol 400 Drugs 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
230000008569 process Effects 0.000 description 4
229960004063 propylene glycol Drugs 0.000 description 4
239000002516 radical scavenger Substances 0.000 description 4
238000012552 review Methods 0.000 description 4
108060008226 thioredoxin Proteins 0.000 description 4
230000001052 transient effect Effects 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
239000004474 valine Substances 0.000 description 4
108700010070 Codon Usage Proteins 0.000 description 3
241000702421 Dependoparvovirus Species 0.000 description 3
102400000686 Endothelin-1 Human genes 0.000 description 3
101800004490 Endothelin-1 Proteins 0.000 description 3
108010074860 Factor Xa Proteins 0.000 description 3
108010060309 Glucuronidase Proteins 0.000 description 3
102000053187 Glucuronidase Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108020005350 Initiator Codon Proteins 0.000 description 3
102100027612 Kallikrein-11 Human genes 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
101710182846 Polyhedrin Proteins 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
241000125945 Protoparvovirus Species 0.000 description 3
101500027366 Rattus norvegicus Atrial natriuretic peptide Proteins 0.000 description 3
108020004459 Small interfering RNA Proteins 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
101710152431 Trypsin-like protease Proteins 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
201000006754 cone-rod dystrophy Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
230000035772 mutation Effects 0.000 description 3
210000004897 n-terminal region Anatomy 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000000813 peptide hormone Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
230000001323 posttranslational effect Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000035939 shock Effects 0.000 description 3
239000004055 small Interfering RNA Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000003146 transient transfection Methods 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
108010025188 Alcohol oxidase Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
241000713842 Avian sarcoma virus Species 0.000 description 2
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
239000005496 Chlorsulfuron Substances 0.000 description 2
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
108091060211 Expressed sequence tag Proteins 0.000 description 2
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
108010093031 Galactosidases Proteins 0.000 description 2
102000002464 Galactosidases Human genes 0.000 description 2
102100039556 Galectin-4 Human genes 0.000 description 2
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
239000012097 Lipofectamine 2000 Substances 0.000 description 2
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
108010091175 Matriptase Proteins 0.000 description 2
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
108090000028 Neprilysin Proteins 0.000 description 2
102000003729 Neprilysin Human genes 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
108020004711 Nucleic Acid Probes Proteins 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 2
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
206010042602 Supraventricular extrasystoles Diseases 0.000 description 2
241000255985 Trichoplusia Species 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
108020002494 acetyltransferase Proteins 0.000 description 2
102000005421 acetyltransferase Human genes 0.000 description 2
230000009471 action Effects 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229940126575 aminoglycoside Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
235000010208 anthocyanin Nutrition 0.000 description 2
229930002877 anthocyanin Natural products 0.000 description 2
239000004410 anthocyanin Substances 0.000 description 2
150000004636 anthocyanins Chemical class 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920003086 cellulose ether Chemical class 0.000 description 2
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
210000005220 cytoplasmic tail Anatomy 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000009368 gene silencing by RNA Effects 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000002837 heart atrium Anatomy 0.000 description 2
230000004217 heart function Effects 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
230000002363 herbicidal effect Effects 0.000 description 2
239000004009 herbicide Substances 0.000 description 2
101150113423 hisD gene Proteins 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000001969 hypertrophic effect Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000010354 integration Effects 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
239000002853 nucleic acid probe Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
238000002515 oligonucleotide synthesis Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000012743 protein tagging Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940094937 thioredoxin Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
101150081616 trpB gene Proteins 0.000 description 2
101150111232 trpB-1 gene Proteins 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
PQVHMOLNSYFXIJ-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazole-3-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)C(=O)O PQVHMOLNSYFXIJ-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000713826 Avian leukosis virus Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
101001012262 Bos taurus Enteropeptidase Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
241000388186 Deltapapillomavirus 4 Species 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
238000011891 EIA kit Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
102000018389 Exopeptidases Human genes 0.000 description 1
108010091443 Exopeptidases Proteins 0.000 description 1
108010074864 Factor XI Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010016803 Fluid overload Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 description 1
101001012451 Homo sapiens Enteropeptidase Proteins 0.000 description 1
101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 description 1
101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
229920000881 Modified starch Chemical class 0.000 description 1
101000638178 Mus musculus Transmembrane protease serine 2 Proteins 0.000 description 1
241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010037368 Pulmonary congestion Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
241000713896 Spleen necrosis virus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108091005956 Type II transmembrane proteins Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
208000009982 Ventricular Dysfunction Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000012436 analytical size exclusion chromatography Methods 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940125364 angiotensin receptor blocker Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000424 bronchial epithelial cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000007894 caplet Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
239000000284 extract Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000004041 inotropic agent Substances 0.000 description 1
229940124975 inotropic drug Drugs 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000002923 metal particle Substances 0.000 description 1
CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
229940054205 natrecor Drugs 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100001222 nononcogenic Toxicity 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000031787 nutrient reservoir activity Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000001581 pretranslational effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
238000012514 protein characterization Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical class C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000006815 ventricular dysfunction Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU2004248192A 2003-06-11 2004-06-09 Novel modified corin molecules having substitute activation sequences and uses thereof Abandoned AU2004248192A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47768303P	2003-06-11	2003-06-11
US60/477,683		2003-06-11
PCT/US2004/018669 WO2004111225A1 (en)	2003-06-11	2004-06-09	Novel modified corin molecules having substitute activation sequences and uses thereof

Publications (1)

Publication Number	Publication Date
AU2004248192A1 true AU2004248192A1 (en)	2004-12-23

Family

ID=33551745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004248192A Abandoned AU2004248192A1 (en)	2003-06-11	2004-06-09	Novel modified corin molecules having substitute activation sequences and uses thereof

Country Status (15)

Country	Link
US (1)	US7176013B2 (no)
EP (1)	EP1636356A1 (no)
JP (1)	JP2007502132A (no)
KR (1)	KR20060022683A (no)
CN (2)	CN101109011A (no)
AU (1)	AU2004248192A1 (no)
BR (1)	BRPI0411353A (no)
CA (1)	CA2527361A1 (no)
IL (1)	IL172095A0 (no)
MX (1)	MXPA05013321A (no)
NO (1)	NO20060144L (no)
PL (1)	PL379196A1 (no)
RU (1)	RU2006100035A (no)
WO (1)	WO2004111225A1 (no)
ZA (1)	ZA200600224B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050026255A1 (en) *	2002-06-25	2005-02-03	Morser John Michael	Corin, a serine protease
TW200723151A (en) *	2005-12-07	2007-06-16	Era Digital Media Co	Business website method
WO2009120760A1 (en) *	2008-03-28	2009-10-01	The Cleveland Clinic Foundation	Corin for treating obesity and diabetes
US20110306069A1 (en)	2009-02-19	2011-12-15	Qingyu Wu	Corin As A Marker For Heart Failure
US10314894B2 (en) *	2014-02-12	2019-06-11	The Cleveland Clinic Foundation	Treatment of cardio-renal disease using PCSK6
EP3422845B1 (en)	2016-02-29	2021-06-02	Regeneron Pharmaceuticals, Inc.	Rodents having a humanized tmprss gene
CN105734070A (zh) *	2016-04-11	2016-07-06	苏州大学	Corin基因变异体及其用途
CN108066286B (zh) *	2016-11-10	2021-06-29	复旦大学	炔丙基半胱氨酸纳米粒长循环脂质体及其制备方法和用途
CN118530307B (zh) *	2024-06-14	2025-09-09	中国人民解放军军事科学院军事医学研究院	一种阻断pts途径的多肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO882226L (no) *	1987-05-22	1988-11-23	Zymogenetics Inc	Fibrinolytiske proteiner.
US5869637A (en)	1996-07-22	1999-02-09	Incyte Pharmaceuticals, Inc.	Human Kallikrein
WO1998024886A1 (en) *	1996-12-04	1998-06-11	Brigham And Women's Hospital, Inc.	Mast cell protease that cleaves fibrinogen
WO1998036054A1 (en)	1997-02-13	1998-08-20	Amrad Operations Pty. Ltd.	Novel molecules
JP3947653B2 (ja) *	1997-08-22	2007-07-25	ロシュダイアグノスティックスゲーエムベーハー	プロテアーゼの自己触媒的に活性化可能なチモーゲン前駆体及びそれらの使用
EP0927764B1 (de)	1997-12-03	2004-05-26	Boehringer Mannheim Gmbh	Chimäre Serinproteasen
ATE397074T1 (de) *	1998-06-05	2008-06-15	Bayer Schering Pharma Ag	Corin, eine serinprotease
US6420157B1 (en) *	1999-04-30	2002-07-16	Ortho-Mcneil Pharmaceutical, Inc.	Zymogen activation system
CA2396774A1 (en) *	2000-02-03	2001-08-09	Corvas International, Inc.	Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP2004503219A (ja) *	2000-06-19	2004-02-05	ダイアックス　コーポレーション	新規エンテロキナーゼ開裂配列
SK6312002A3 (en) *	2000-09-04	2002-09-10	Hyo-Joon Kim	Mimetic peptides for epitope of apolipoprotein b-110, concatemer and modified peptides thereof, and the vaccine composition comprising the same
FR2831170B1 (fr) *	2001-10-19	2004-03-19	Inst Nat Sante Rech Med	Proteines c modifiees activables directement par la thrombine
JP2006507813A (ja) *	2002-10-04	2006-03-09	シエーリングアクチエンゲゼルシャフト	置換体活性化配列を有する修飾されたヘプシン分子及びその使用

2004
- 2004-06-09 CN CNA2007101280546A patent/CN101109011A/zh active Pending
- 2004-06-09 PL PL379196A patent/PL379196A1/pl not_active Application Discontinuation
- 2004-06-09 KR KR1020057023612A patent/KR20060022683A/ko not_active Withdrawn
- 2004-06-09 AU AU2004248192A patent/AU2004248192A1/en not_active Abandoned
- 2004-06-09 US US10/865,978 patent/US7176013B2/en not_active Expired - Fee Related
- 2004-06-09 RU RU2006100035/13A patent/RU2006100035A/ru not_active Application Discontinuation
- 2004-06-09 CA CA002527361A patent/CA2527361A1/en not_active Abandoned
- 2004-06-09 JP JP2006533746A patent/JP2007502132A/ja active Pending
- 2004-06-09 MX MXPA05013321A patent/MXPA05013321A/es not_active Application Discontinuation
- 2004-06-09 CN CNA2004800230099A patent/CN1836037A/zh active Pending
- 2004-06-09 BR BRPI0411353-5A patent/BRPI0411353A/pt not_active IP Right Cessation
- 2004-06-09 EP EP04755046A patent/EP1636356A1/en not_active Withdrawn
- 2004-06-09 WO PCT/US2004/018669 patent/WO2004111225A1/en not_active Ceased
2005
- 2005-11-22 IL IL172095A patent/IL172095A0/en unknown
2006
- 2006-01-10 ZA ZA200600224A patent/ZA200600224B/en unknown
- 2006-01-10 NO NO20060144A patent/NO20060144L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI0411353A (pt)	2006-07-11
CA2527361A1 (en)	2004-12-23
WO2004111225A1 (en)	2004-12-23
US20050003416A1 (en)	2005-01-06
CN101109011A (zh)	2008-01-23
MXPA05013321A (es)	2006-03-09
NO20060144L (no)	2006-01-10
PL379196A1 (pl)	2006-07-24
IL172095A0 (en)	2009-02-11
ZA200600224B (en)	2007-04-25
JP2007502132A (ja)	2007-02-08
RU2006100035A (ru)	2006-08-27
KR20060022683A (ko)	2006-03-10
WO2004111225A8 (en)	2006-04-06
EP1636356A1 (en)	2006-03-22
US7176013B2 (en)	2007-02-13
CN1836037A (zh)	2006-09-20

Publication	Publication Date	Title
US5869637A (en)	1999-02-09	Human Kallikrein
US9856467B2 (en)	2018-01-02	Modified factor X polypeptides and uses thereof
US7070977B2 (en)	2006-07-04	Human serine protease D-G polypeptide
JP6514893B2 (ja)	2019-05-15	止血を調節するための組成物および方法
US7176013B2 (en)	2007-02-13	Modified corin molecules having substitute activation sequences and uses thereof
US6379913B1 (en)	2002-04-30	Human serine carboxypeptidase
US7238776B2 (en)	2007-07-03	TNF binding proteins
US5989890A (en)	1999-11-23	Compositions and methods for PACE 4 and 4.1 gene and polypeptides in cells
US6274717B1 (en)	2001-08-14	Splicing variant of human membrane-type matrix metalloproteinease-5 (MT-MMP5-L)
USH1973H1 (en)	2001-07-03	Human neutrophil collagenase splice variant
WO2004099402A1 (en)	2004-11-18	Glycosylation variants of bace
CA2362330A1 (en)	2000-08-24	A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen
HK1109171A (en)	2008-05-30	Novel modified corin molecules having substitute activation sequences and uses thereof
US20050164366A1 (en)	2005-07-28	Tissue plasminogen activator-like protease
US6784288B2 (en)	2004-08-31	Polynucleotide and polypeptide sequences of monkey cathepsin S
US6110717A (en)	2000-08-29	Human RCE1
JP2003116568A (ja)	2003-04-22	血液凝固阻害活性を有するブラジルサシガメ由来のＴｉ−１蛋白質
JP2003116574A (ja)	2003-04-22	血液凝固阻害活性を有するブラジルサシガメ由来のＴｉ−２蛋白質
WO1999002664A1 (en)	1999-01-21	Human n-arginine dibasic convertase
HK1210790B (en)	2019-08-09	Modified factor x polypeptides and uses thereof
WO2002020805A2 (en)	2002-03-14	Regulation of human carboxypeptidase-like enzyme

Legal Events

Date	Code	Title	Description
2006-09-21	TC	Change of applicant's name (sec. 104)	Owner name: SCHERING AKTIENGESELLSCHAFT Free format text: FORMER NAME: SCHERING AKITENGESELLSCHAFT
2010-01-14	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application

Date

Code

Title

Description

2006-09-21

Change of applicant's name (sec. 104)

Owner name: SCHERING AKTIENGESELLSCHAFT

Free format text: FORMER NAME: SCHERING AKITENGESELLSCHAFT

2010-01-14

MK4

Application lapsed section 142(2)(d) - no continuation fee paid for the application